|
MannKind (MNKD) Stock Pops On United Therapeutics News By Joshua Rodriguez - September 11, 2019 0 MannKind MNKD Stock News MannKind Corporation (NASDAQ: MNKD) is headed up in the market this morning, trading on gains of more than 8%. However, I believe that once the reason for the gains really hits the mainstream, we’re going to see quite a bit more movement. If you do some digging, you’ll see that the company hasn’t issued any press releases or SEC filings. In fact, the company hasn’t released anything, but it’s partner, United Therapeutics (NASDAQ: UTHR), has. Here’s what’s happening: Stop wasting your time! Start finding winning trades in minutes with Trade Ideas! UTHR News Sends MNKD Stock Up In a press release issued this morning, United Therapeutics Corporation said that the FDA has accepted the New Drug Application for Trevyent for review. It is hoped that the drug will be approved by the FDA for the treatment of pulmonary arterial hypertension (PAH). So, what does this have to do with MannKind? A while ago, MNKD and UTHR announced an agreement. Under the terms of the agreement, United Therapeutics would test the company’s Technosphere technology to create an inhalable powder version of Trevyent. Importantly, the clinical trial, assessing the inhalable version of Trevyent was expected to begin in August of this year, according to ClinicalTrials.gov. While we haven’t heard any news associated with the trial initiation, this is likely around the corner. Considering the fact that the FDA has accepted the NDA for Trevyent, UTHR is well on its way to earning an approval. Should the drug be approved, for the inhaled version of it to receive approval, MNKD and UTHR will only need to show that the drug is safely and effectively deliverable through this vehicle, setting the stage for MannKind to earn milestone and royalty payments associated with it. Investors Haven’t Caught Up To The News Because MannKind had nothing to do with the news issued today, it seems as though investors haven’t quite caught up. Those searching are finding little to nothing as a reason for the gains. Nonetheless, when the masses see that a NDA was acceped by the FDA surrounding a drug that MNKD and UTHR are working on together. Should an approval take place, the opportunity here is going to be massive. So, keep an eye and try to beat the masses to the jump. |
|
| aus der Diskussion: | Mannkind, Game-Chancer in Sachen Diabetik? |
| Autor (Datum des Eintrages): | Magnetfeldfredy (12.09.19 07:06:43) |
| Beitrag: | 5,571 von 6,825 (ID:61463960) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |